Amneal Pharmaceuticals, Inc. (AMRX)
21.38
-0.32
(-1.50%)
USD |
NASDAQ |
Nov 13, 16:00
21.38
0.00 (0.00%)
After-Hours: 19:59
Amneal Pharmaceuticals Net Income (Quarterly) : 12.31M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 12.31M |
| June 30, 2026 | 69.61M |
| March 31, 2026 | 78.00M |
| December 31, 2025 | 49.57M |
| September 30, 2025 | 18.13M |
| June 30, 2025 | 35.61M |
| March 31, 2025 | 24.62M |
| December 31, 2024 | -20.74M |
| September 30, 2024 | 11.76M |
| June 30, 2024 | 16.79M |
| March 31, 2024 | -81.68M |
| December 31, 2023 | -93.34M |
| September 30, 2023 | 25.03M |
| June 30, 2023 | 29.68M |
| March 31, 2023 | -10.09M |
| December 31, 2022 | -5.858M |
| September 30, 2022 | -2.39M |
| June 30, 2022 | -240.08M |
| March 31, 2022 | -6.46M |
| December 31, 2021 | -20.46M |
| September 30, 2021 | -6.092M |
| June 30, 2021 | 32.18M |
| March 31, 2021 | 14.54M |
| December 31, 2020 | -6.962M |
| September 30, 2020 | -22.03M |
| Date | Value |
|---|---|
| June 30, 2020 | -23.94M |
| March 31, 2020 | 121.52M |
| December 31, 2019 | -64.90M |
| September 30, 2019 | -363.39M |
| June 30, 2019 | -50.53M |
| March 31, 2019 | -124.75M |
| December 31, 2018 | -20.33M |
| September 30, 2018 | 17.46M |
| June 30, 2018 | -49.75M |
| March 31, 2018 | 0.117M |
| December 31, 2017 | 0.625M |
| September 30, 2017 | 0.342M |
| June 30, 2017 | 0.302M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | -279.58M |
| September 30, 2016 | -179.34M |
| June 30, 2016 | -2.701M |
| March 31, 2016 | -10.41M |
| December 31, 2015 | 11.43M |
| September 30, 2015 | 35.76M |
| June 30, 2015 | -1.852M |
| March 31, 2015 | -6.333M |
| December 31, 2014 | 0.12M |
| September 30, 2014 | 15.74M |
| June 30, 2014 | 35.07M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 55.46M |
| Pfizer Inc. | 3.251B |
| Liquidia Corp. | -236.33M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 6.451B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 862.68M |
| Total Expenses (Quarterly) | 884.38M |
| EPS Diluted (Quarterly) | -0.0646 |
| Enterprise Value | 10.78B |
| Gross Profit Margin (Quarterly) | 38.73% |
| Profit Margin (Quarterly) | 1.43% |
| Earnings Yield | 1.91% |
| Operating Earnings Yield | 7.45% |
| Normalized Earnings Yield | 2.542 |